Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Cardiology

Treating Chagas Heart Disease (Standard of Care)

At a Glance

Chagas cardiomyopathy is managed with individualized heart-failure medicines, blood thinners when needed, and rhythm treatments such as pacemakers, defibrillators, or ablation. Advanced disease may require transplant with PCR blood testing and prompt antiparasitic treatment for reactivation.

When Chagas disease begins to affect the heart, the focus of your medical care shifts from killing the parasite to protecting the heart muscle and managing its electrical system. There is no single “Chagas heart pill”; instead, doctors use a combination of therapies proven to work for many types of heart failure, tailored to the unique way Chagas causes damage [1].

Protecting the Heart’s Pump

If the disease has weakened your heart’s ability to pump (a condition called Heart Failure with Reduced Ejection Fraction, or HFrEF), the current gold standard is called Guideline-Directed Medical Therapy (GDMT). This involves “four pillars” of medication that work together to take the stress off your heart [2][1]. Much of this evidence is extrapolated from general heart-failure populations.

  • ARNI or ACEi/ARB: Medications like sacubitril/valsartan (ARNI) or enalapril (ACEi/ARB) help relax blood vessels and lower the workload on the heart [3][1]. You take one or the other, not both.
  • Beta-blockers: These slow your heart rate and protect the muscle from the harmful effects of stress hormones [1].
  • MRA (Mineralocorticoid Receptor Antagonists): Drugs like spironolactone help block hormones that contribute to heart scarring and fluid retention [4].
  • SGLT2 Inhibitors: Originally for diabetes, these have been found to significantly reduce heart failure hospitalizations [2][5].
    (Note: Diuretics, or water pills, may also be added to manage symptomatic fluid retention. Treatment is tailored based on your ejection fraction, blood pressure, kidney function, and tolerability).

Stroke Prevention (Anticoagulation)

Because Chagas carries a risk of cardioembolic stroke, your doctor will assess your need for an anticoagulant (blood thinner). This is highly individualized and is especially considered if you have atrial fibrillation, a documented intracardiac thrombus, or a high-risk apical aneurysm.

Managing Electrical “Short Circuits”

Chagas is famous for damaging the heart’s electrical system, which can cause the heart to beat too slowly or dangerously fast [6].

Pacemakers

Because the parasite often damages the heart’s “natural pacemaker,” many patients develop a very slow heart rate or “blocks” where the electrical signal doesn’t get through [7]. A pacemaker is a small device implanted under the skin that sends tiny electrical pulses to keep your heart beating at a healthy speed [6].

ICDs (Defibrillators)

For patients at risk of a life-threatening fast rhythm (ventricular tachycardia), an ICD (Implantable Cardioverter-Defibrillator) may be recommended [8]. Unlike a pacemaker, an ICD monitors every heartbeat and can deliver a life-saving “shock” to reset the heart if it enters a dangerous rhythm [9]. ICD decisions depend on multiple factors, including prior cardiac arrest, sustained ventricular tachycardia, ejection fraction, and syncope—not just a simple clinical score [10].

Specialized Procedures: Catheter Ablation

If you have frequent episodes of a racing heart that medications cannot control, you may need a catheter ablation. In this procedure, a doctor uses a thin tube to find and “burn” the small areas of scar tissue causing the electrical short circuit [11].

In Chagas, the scarring often happens on the epicardium (the outside surface of the heart) [12]. Because of this, Chagas ablations often require a specialized “epicardial approach,” where the doctor accesses the outside of the heart rather than just the inside [11][13].

Advanced Options: Heart Transplantation

For patients with end-stage heart failure where other treatments are no longer enough, a heart transplant is a very effective option [14]. Chagas patients often do as well as, or even better than, patients with other types of heart disease after a transplant [15].

Managing Parasite Reactivation

One unique aspect of Chagas transplants is the risk of reactivation [16]. Because you must take medications to suppress your immune system so it doesn’t reject the new heart, the Chagas parasite can sometimes “wake up” and start multiplying again [17].

  • Monitoring: You will have frequent blood tests using PCR (a very sensitive DNA test) to look for the parasite [18].
  • Preemptive Treatment: If the PCR shows the parasite levels are rising, your doctors will give you antiparasitic medication (benznidazole) immediately to stop the reactivation before it causes symptoms [18][19].

By combining these advanced heart failure treatments with careful monitoring, many patients with Chagas cardiomyopathy are able to maintain a high quality of life for many years.

Common questions in this guide

What medicines are used to treat Chagas cardiomyopathy?
When Chagas cardiomyopathy causes reduced pumping strength, doctors commonly use four groups of heart-failure medicines: an ARNI or ACE inhibitor/ARB, a beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor. Diuretics may be added for fluid retention, and the combination is adjusted for blood pressure, kidney function, ejection fraction, and side effects.
Could I need a pacemaker or defibrillator because of Chagas heart disease?
A pacemaker may be recommended when Chagas disease causes a very slow heartbeat or a blockage in the heart’s electrical signals. An implantable cardioverter-defibrillator, or ICD, may be considered when there is a risk of a dangerous fast rhythm; the decision can include prior cardiac arrest, sustained ventricular tachycardia, heart-pumping strength, and fainting.
Do I need a blood thinner for Chagas cardiomyopathy?
Not everyone with Chagas cardiomyopathy needs an anticoagulant, or blood thinner. Your clinician may consider one if you have atrial fibrillation, a clot inside the heart, or a high-risk bulge in the heart’s apex, along with your overall bleeding and stroke risks.
How is ablation used for Chagas-related heart rhythm problems?
Catheter ablation may be used when repeated racing-heart episodes are not controlled by medication. Because Chagas scarring often lies on the outside surface of the heart, the procedure may require an epicardial approach that reaches this outer surface.
Can a heart transplant help with advanced Chagas cardiomyopathy?
A heart transplant can be an effective option when Chagas cardiomyopathy causes end-stage heart failure that no longer responds well enough to other treatment. After transplant, immune-suppressing medicines can allow the parasite to reactivate, so close monitoring and prompt treatment are part of ongoing care.
How do doctors watch for Chagas reactivation after a heart transplant?
Doctors use frequent blood tests called PCR to look for the parasite’s genetic material after transplantation. If parasite levels begin to rise, benznidazole may be started promptly to stop reactivation before symptoms develop.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my heart failure treatment following the 'four pillars' of Guideline-Directed Medical Therapy (GDMT)?
  2. 2.Do I have any rhythm abnormalities or stroke risks that suggest I should be on a blood thinner?
  3. 3.Based on my EKG and heart function, am I a candidate for a pacemaker or an ICD to prevent sudden cardiac arrest?
  4. 4.If I need a procedure for my heart rhythm (ablation), do you have experience with the 'epicardial' approach used in Chagas?
  5. 5.If we discuss a heart transplant, how often will I be tested for parasite reactivation using PCR?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Adherence to Guideline-Directed Medical Therapy Target in patients with heart failure and reduced ejection fraction: a cross-sectional study.

    Costa FF, Chagas AKR, Santos ACML, et al.

    Sao Paulo medical journal = Revista paulista de medicina 2025; (143(3)):e2023315 doi:10.1590/1516-3180.2023.0315.R2.13082024.

    PMID: 40332281
  2. 2

    The effects of antidiabetic agents on heart failure.

    Wijnen M, Duschek EJJ, Boom H, van Vliet M

    Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2022; (30(2)):65-75 doi:10.1007/s12471-021-01579-2.

    PMID: 34097240
  3. 3

    ANSWER-HF: sacubitril-valsartan reduces NT-proBNP in heart failure due to Chagas cardiomyopathy despite no reverse remodeling.

    Martins EB, Madrini V, Ramos Souza PV, et al.

    Heart failure reviews 2026; (31(1)).

    PMID: 41870675
  4. 4

    Up-titration of medication in patients with new-onset heart failure with and without atrial fibrillation.

    Zandijk AJL, Santema BT, Inkelaar FDJ, et al.

    ESC heart failure 2025; (12(3)):1703-1713 doi:10.1002/ehf2.15188.

    PMID: 39968941
  5. 5

    Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.

    Butt JH, Kondo T, Jhund PS, et al.

    Journal of the American College of Cardiology 2022; (80(18)):1705-1717 doi:10.1016/j.jacc.2022.08.718.

    PMID: 36041668
  6. 6

    The Prevalence of Chagas Disease Among Latin American Immigrants with Pacemakers in Los Angeles, California.

    Park S, Sanchez DR, Traina MI, et al.

    The American journal of tropical medicine and hygiene 2017; (96(5)):1139-1142 doi:10.4269/ajtmh.16-0826.

    PMID: 28500812
  7. 7

    An Infrequent Cause of Apical Ventricular Aneurysm in the United States.

    Taleb MM

    Heart views : the official journal of the Gulf Heart Association 2017; (18(2)):54-57 doi:10.4103/1995-705X.208675.

    PMID: 28706597
  8. 8

    Implantable cardioverter-defibrillator in Chagas heart disease: A systematic review and meta-analysis of observational studies.

    Carmo AAL, de Sousa MR, Agudelo JF, et al.

    International journal of cardiology 2018; (267()):88-93 doi:10.1016/j.ijcard.2018.05.091.

    PMID: 29871807
  9. 9

    Long-term follow-up of Chagas heart disease patients receiving an implantable cardioverter-defibrillator for secondary prevention.

    Pavão MLRC, Arfelli E, Scorzoni-Filho A, et al.

    Pacing and clinical electrophysiology : PACE 2018; (41(6)):583-588 doi:10.1111/pace.13333.

    PMID: 29578582
  10. 10

    Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial.

    Martinelli-Filho M, Marin-Neto JA, Scanavacca MI, et al.

    JAMA cardiology 2024; (9(12)):1073-1081 doi:10.1001/jamacardio.2024.3169.

    PMID: 39356542
  11. 11

    Outcomes comparison between catheter ablation of ventricular tachycardia in Chagas disease versus ischemic and dilated cardiomyopathy - a retrospective cohort study.

    Kulchetscki RM, Rodrigues LV, Pisani CF, et al.

    Lancet regional health. Americas 2026; (55()):101394 doi:10.1016/j.lana.2026.101394.

    PMID: 41994350
  12. 12

    Advanced management of ventricular arrhythmias in chronic Chagas cardiomyopathy.

    Santacruz D, Rosas F, Hardy CA, et al.

    Heart rhythm O2 2021; (2(6Part B)):807-818 doi:10.1016/j.hroo.2021.10.010.

    PMID: 34988532
  13. 13

    Advanced Therapies for Ventricular Arrhythmias in Patients With Chagasic Cardiomyopathy: JACC State-of-the-Art Review.

    Romero J, Velasco A, Pisani CF, et al.

    Journal of the American College of Cardiology 2021; (77(9)):1225-1242 doi:10.1016/j.jacc.2020.12.056.

    PMID: 33663741
  14. 14

    Transplantation for chagas' disease: closing the knowledge gap.

    La Hoz RM

    Current opinion in infectious diseases 2022; (35(5)):397-403 doi:10.1097/QCO.0000000000000868.

    PMID: 35942849
  15. 15

    Survival after heart transplantation for Chagas cardiomyopathy using a conventional protocol: A 10-year experience in a single center.

    Echeverría LE, Figueredo A, Rodriguez MJ, et al.

    Transplant infectious disease : an official journal of the Transplantation Society 2021; (23(4)):e13549 doi:10.1111/tid.13549.

    PMID: 33345420
  16. 16

    Reactivation of Trypanosoma cruzi infection in immunosuppressed patients: a systematic review and meta-analysis.

    Antequera A, Molin-Veglia AD, López-Alcalde J, et al.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2024; (30(8)):980-988 doi:10.1016/j.cmi.2024.04.013.

    PMID: 38697392
  17. 17

    Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016.

    Gray EB, La Hoz RM, Green JS, et al.

    Transplant infectious disease : an official journal of the Transplantation Society 2018; (20(6)):e12996 doi:10.1111/tid.12996.

    PMID: 30204269
  18. 18

    Chagas disease in the immunocompromised host.

    Clark EH, Bern C

    Current opinion in infectious diseases 2024; (37(5)):333-341 doi:10.1097/QCO.0000000000001035.

    PMID: 38963802
  19. 19

    Sequential measurement of Trypanosoma cruzi parasitic load in endomyocardial biopsies for early detection and follow-up of Chagas disease reactivation after heart transplantation.

    Benvenuti LA, Roggério A, Nishiya AS, et al.

    Transplant infectious disease : an official journal of the Transplantation Society 2020; (22(1)):e13209 doi:10.1111/tid.13209.

    PMID: 31698532

This page describes Chagas cardiomyopathy treatment for informational purposes only and does not constitute medical advice. Your cardiologist and infectious disease team should tailor medicines, devices, procedures, and transplant monitoring to your situation.

Get notified when new evidence is published on Chagas cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.